Market Cap 412.45M
Revenue (ttm) 10.12M
Net Income (ttm) -220.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,180.43%
Debt to Equity Ratio 0.00
Volume 2,084,200
Avg Vol 1,305,788
Day's Range N/A - N/A
Shares Out 266.09M
Stochastic %K 50%
Beta 2.07
Analysts Strong Sell
Price Target $10.07

Latest News on AUTL

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 2:57 PM EST - 5 months ago

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript


Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 12:05 AM EDT - 8 months ago

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript


Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript

May 17, 2024, 12:55 PM EDT - 11 months ago

Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript


Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 7:00 AM EST - 1 year ago

Autolus Announces Pricing of Underwritten Offering


Autolus Upgrades Leadership And Faces CAR-T Approval

Feb 6, 2024, 9:52 AM EST - 1 year ago

Autolus Upgrades Leadership And Faces CAR-T Approval


Autolus: CAR-T Therapy Looks Promising

Sep 11, 2023, 6:41 AM EDT - 1 year ago

Autolus: CAR-T Therapy Looks Promising


Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket

Jun 30, 2023, 7:34 PM EDT - 1 year ago

Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket